Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Scientists identify common symptom patterns in post-COVID-19 vaccination syndrome

16

Mar 2026

Scientists identify common symptom patterns in post-COVID-19 vaccination syndrome

A registry study across 14 Japanese clinics analyzed 179 cases of post-COVID-19 vaccination syndrome (PCVS) and identified 493 adverse events affecting multiple organ systems. Most symptoms appeared within 90 days, but some occurred much later, highlighting the need for continued vaccine safety monitoring and better clinical frameworks for persistent post-vaccination symptoms.

Rising temperatures may increase global physical inactivity by 2050

16

Mar 2026

Rising temperatures may increase global physical inactivity by 2050

Rising temperatures due to climate change could drive millions more adults globally into physical inactivity by 2050, being linked to hundreds of thousands of premature deaths and billions of dollars in lost productivity, suggests a modelling study published in The Lancet Global Health journal.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.